"Ten or 20 years from now, we will be sending our patients to the laboratory to characterize them in terms of genetic polymorphisms and/or to an imaging laboratory. Then based on those findings, and on the clinical presentation of the patient, we will be able to do what we can’t do right now, which is […]
[Dr. David Healy – Rxisk]
for the best film…
Sometimes a piece of data comes along that’s interesting no matter what it means – something to ponder. This is the US geographic distribution of psychotropic drug use: stimulants, antidepressants, and antipsychotics. It’s from a Yale study using a national prescription database by zip code showing wide geographic variations in the prescription rate of psychotropic […]
Among the advantages of parenthood, one is having a techno-daughter who can bail you out when you are hopelessly stumped by the Twitter plug-in that Tweets when you post [whatever that means]… Update: By golly, it worked!
Sessions Will Provide In-Depth Look at New DSM Psychiatric News by Kuhl Emily, Ph.D. February 15, 2013 … Beyond merely summarizing the most notable revisions, speakers will articulate the underlying rationales of the changes and how DSM-5 can be implemented in clinical practice and in research settings. Reviews of the final, approved criteria from specific […]
Of late, I find myself drawn to how things play out over time in the world of PHARMA. In the January Journal of the American Academy of Child and Adolescent Psychiatry [JAACAP], I ran across some letters about the N.I.M.H. Treatment of Early Age Mania [TEAM] Study which ran from 2003-2008. It compared Risperidone [Risperdal®], […]
Big pharma often commits corporate crime, and this must be stopped by Peter C Gøtzsche professor Nordic Cochrane Centre, Copenhagen, Denmark British Medical Journal 2012;345:e8462 doi: 10.1136/bmj.e8462. When a drug company commits a serious crime, the standard response from the industry is that there are bad apples in any enterprise. Sure, but the interesting question […]
Data Transparency Independent of the outcome of the Baum Hedlund suit [Laura A. Plumlee et. al. v. Pfizer] in the courts, I think their complaint was illuminating, at least to me. I didn’t know that Zoloft was the best seller in the antidepressant market, or the story of its approval and its rise to those […]
And so to what was riding on those decisions along the way? An absolute fortune was riding on every single one of them – on the jury-rigged protocol 103, or the unreplicable protocol 104, on the relapse prevention protocol 320 with its massive drop-out rates, on Paul Leber’s F.D.A. N.D.A. speech, and on the deceptive […]